Posted on 29/07/2010 in Scientific Thermo Fisher Scientific has experienced a strong second quarter in 2010, thanks to the success of its investment and new product initiatives.
The science company posted a seven per cent year-on-year increase in revenues during the quarter to $2.7 billion (1.7 billion pounds), while also achieving record-breaking earnings per share figures.
Its analytical technologies and laboratory products and services segments both benefited from this trend towards growth, while its molecular and cellular biology activities were recently bolstered by the acquisition of Fermentas.
The firm will also look to support its future expansion with new innovations in the fields of life sciences mass spectrometry, clinical research and specialty diagnostics.
Marc Casper, president and chief executive officer of Thermo Fisher Scientific, said: "We successfully leveraged our top-line performance to achieve solid operating margin expansion and double-digit EPS growth."
Last week, Thermo Fisher Scientific highlighted the benefits its Finesse Microtome system has brought to the Parkinson's UK and MS Society Tissue Bank, including allowing the facility to handle larger sample sizes. Other news stories from 29/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
